LISCure Biosciences researches and develops bacteria-mediated immunotherapy that can be used alone or in combination with other drugs. The company is developing treatments targeting tumors, degenerative neurological diseases, autoimmune diseases, metabolic diseases and other major indications. LISCure currently has seven drug pipelines and two health‑functioning food pipelines, and is considering adding two more pipelines. Established in December 2018 and based in Seoul, the company raised seed financing to advance its programs. It intends to use the funds to strengthen its research and development capabilities around its core technologies. The focus is on expanding and progressing its bacteria-mediated therapeutic platform toward clinical and product objectives.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2019